Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 11/20 | 0.62 |
| ▸ | CASP7 | P55210 | 7/20 | 0.57 |
| ▸ | CASP1 | P29466 | 5/20 | 0.57 |
| ▸ | CASP9 | P55211 | 4/20 | 0.57 |
| ▸ | MME | P08473 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | CASP4 | P49662 | 3/20 | 0.54 |
| ▸ | CASP10 | Q92851 | 3/20 | 0.53 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | CASP5 | P51878 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614741 | 1.00 | CASP3 (0.62) | CASP3CASP7CASP1CASP9MME | |
| SCHEMBL7112627 | 0.96 | CASP3 (0.58) | CASP3CASP7CASP1CASP9MME | |
| SCHEMBL3692638 | 0.96 | CASP3 (0.58) | CASP3CASP7CASP1CASP9MME | |
| SCHEMBL7383742 | 0.95 | CASP3 (0.67) | CASP3CASP7CASP1CASP9MME | |
| SCHEMBL4420464 | 0.95 | CASP3 (0.67) | CASP3CASP7CASP1CASP9MME | |
| SCHEMBL3692630 | 0.94 | CASP3 (0.56) | CASP3CASP7CASP1CASP9MME | |
| SCHEMBL18740358 | 0.92 | CASP3 (0.58) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL29453232 | 0.92 | MME (0.58) | CASP3CASP1MMEECE1CTSK | |
| SCHEMBL30579903 | 0.91 | REN (0.59) | CASP3CASP7CASP1CASP9CASP8 | |
| SCHEMBL7155003 | 0.91 | MME (0.59) | CASP3CASP1MMEECE1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050276809-A1 | comprising antibodies that specifically bind caspase-8 as inhibitors; cancer; activation of the receptor-interacting protein (RIP, a serine-threonine kinase) and Jun N-terminal kinase induce cell death with the morphology of autophagy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-15 | — | — | US | claimed |
| US-20130316958-A1 | HIGHLY POTENT PEPTIDES TO CONTROL CANCER AND NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTHERN CALIFORNIA | 2013-11-28 | — | — | US | disclosed |
| WO-2012015836-A1 | HIGHLY POTENT PEPTIDES TO CONTROL CANCER AND NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-02-02 | — | — | WO | disclosed |
| US-7838645-B2 | comprising antibodies that specifically bind caspase-8 as inhibitors; cancer; activation of the receptor-interacting protein (RIP, a serine-threonine kinase) and Jun N-terminal kinase induce cell death with the morphology of autophagy | UNIVERSITY OF MARYLAND COLLEGE PARK (US) | 2010-11-23 | — | — | US | disclosed |
| WO-2010011952-A2 | HIGHLY POTENT PEPTIDES TO CONTROL CANCER AND NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20050276809-A1 | comprising antibodies that specifically bind caspase-8 as inhibitors; cancer; activation of the receptor-interacting protein (RIP, a serine-threonine kinase) and Jun N-terminal kinase induce cell death with the morphology of autophagy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-15 | — | — | US | disclosed |